CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 73 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03718117
NCT03718117N/ACompleted
CompareCT.gov

CHARACTERISTICS OF ADULT PATIENTS TREATED WITH CRIZOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH ALK GENE REARRANGEMENT OR ROS1 GENE REARRANGEMENT IN GENERAL HOSPITALS.

Pfizer·observational·Posted Oct 24, 2018·Updated Sep 27, 2024

In Brief

An observational study for NSCLC and 2 related conditions. Completed, enrolled 73 participants across 26 sites.

Detailed Summary

Descriptive Observational Study. Characteristics Of ALK-positive and ROS1-positive Adults Patients Non-Small Cell Lung Cancer (NSCLC) Treated With Crizotinib Within General Hospitals

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC, Crizotinib, ALK Gene Rearrangement or ROS1 Gene Rearrangement
CountriesFrance
CollaboratorsFrench College of General Hospital Pneumologists (CPHG)

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedOct 24, 2018
Enrollment StartJan 3, 2017
Primary CompletionJul 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 7.7 years ago